Canadian Breast Cancer Symposium

Friday, June 18, 2021 09:30-10:00 AM (ET)

Maximizing Precision in the Treatment of Early Stage Node Positive Breast Cancer - A Case Based Discussion

Join presenters as they apply results from the recent RxPONDER trial in early stage node positive breast cancer to clinical practice.

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

Exact Sciences at 2021 ASCO Annual Meeting

Making cancer care smarter.™

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.